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B.B. Lee*Department of Vascular Surgery, Sungkyunkwan University School of Medicine, and Vascular Malformation
Clinic, Samsung Medical Center, Seoul 135-710, South KoreaObjective. A retrospective review of the results of management of congenital vascular malformation (CVM) patients was
made to assess the efficacy of newly introduced approaches.
Methods. CVMs were categorised according to the Hamburg classification on the basis of minimally invasive tests. Invasive
studies such as angiography are used to provide a road map for treatment. A new multidisciplinary approach was adopted,
which accepts the integration of embolisation and sclerotherapy with traditional surgical therapy. Embolo-sclerotherapy was
used as an independent therapy and as an adjunctive therapy to surgery.
Results. Ninety-nine out of a total of 294 venous malformation patients underwent ethanol sclerotherapy with an
immediate success rate of 98.8%, requiring 419 sessions of treatment. Interim results were excellent with no evidence of
recurrence (mean follow-up 18.2 months). Most of the 25 patients treated surgically received pre-operative embolo-
sclerotherapy, each with excellent interim results and minimum morbidity (mean follow-up 21.2 months). Forty-eight
patients among 76 arteriovenous malformation patients underwent embolo-sclerotherapy independently (32/48) or
adjunctively (16/48). Independent therapy on 32 produced excellent interim results (25/32) requiring a total of 171 sessions
(mean follow-up 19.2 months).
Eighty-nine extratruncal (ET) forms of lymphatic malformations received multiple sessions of sclerotherapy with OK-432
(108/120 sessions) or ethanol (12/20 sessions). OK-432 was used in 51 paediatric patients with the ET form and produced an
excellent response in cystic type lesions (40/45) requiring 61 sessions with no evidence of recurrence (mean follow-up 24.2
months), whereas a mixed result was obtained in the cavernous type (3/6). OK-432 sclerotherapy was used as a pre-operative
adjunctive therapy in 7 patients requiring 21 sessions with 17 cavernous type of the ET form, and produced good to excellent
results after surgical excision of 14 lesions.
Conclusion. New approaches to the treatment of CVMs based on a multidisciplinary approach can improve results by fully
combined surgical treatment with embolo-sclerotherapy.Keywords: Congenital vascular malformations; Hamburg classification; Surgical therapy; Embolo/sclerotherapy; Multi-
disciplinary team approach; Venous malformation; Arteriovenous malformation; Lymphatic malformation.Introduction
Congenital vascular malformations (CVMs) remain
difficult diagnostically and therapeutically despite
continued efforts over the decades. CVMs have a
notorious reputation due to their variety, with a wideng author. B.B. Lee, MD, PhD, FACS, Clinical Professor
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0184+ 14 $35.00/0 q 2004 Elsevier Ltd. All rights reserrange of clinical presentations from a simple birthmark
to a life-threatening condition containing embryonic
remnants of a developmental defect. The condition has
been further complicated by an unpredictable clinical
course, confusing nomenclature, erratic response to
treatment, frequent recurrence, and high morbidity
following conventional treatment.1–4
The poor results of treatment over the last decade,
are partly the result of ill-planned treatment strategies
and a cavalier approach based on limited knowledge
of CVMs.5,6 Recurrence also plays a part as embryonic
remnants of CVMs retain developmental potential.7
Disastrous surgical experiences have allowed illEur J Vasc Endovasc Surg 30, 184–197 (2005)
doi:10.1016/j.ejvs.2004.10.006, available online at http://www.sciencedirect.com onved.
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ment of CVMs.5 The Hamburg classification4,6,8 was
introduced to provide proper information about the
aetiology, anatomy, and pathophysiology of CVMs,
and has became the basis for contemporary diagnosis
and management.4,6 The new concept of a multi-
disciplinary approach9–12 integrates surgical and non-
surgical treatments.1,13–15 We organised the CVM
(congenital vascular malformation) clinic at Samsung
Medical Center, Seoul, Korea as a referral centre, based
on a multidisciplinary approach in 1994. A retro-
spective review of interim results of the diagnosis
and management of CVM patients (January 1995–
December 2001), was made to assess the various issues
raised by this new approach.DiagnosisDefinition (Classification)
The classification of CVMs is difficult, since CVMs are
a group of birth defects that occur as a consequence of
developmental arrest at various stages of embryonic
life. This affects the whole peripheral vascular
(arterial, venous, lymphatic, and capillary) system.
Traditional nomenclature of these various CVMs,
based mainly on of name-based eponyms (e.g.
Klippel–Trenaunay Syndrome, Parkes–Weber Syn-
drome) add further confusion, and therefore a proper
classification of CVMs has been developed to provide
proper aetiological, anatomical, pathophysiology, his-
tological, and embryologic information in addition to
haemodynamic information.3,4 Various classifications
have been proposed, including the (high and low)
flow-based classification, but have failed to fulfil this
requirement.6
A classification was published based on a consen-
sus workshop for CVMs held in Hamburg, Germany,
in 1988 by the ISSVA (International Society of Study of
Vascular Anomaly).4,6 It classified CVMs according to
the predominant vascular defect: arterial, venous, AV
(arteriovenous) shunting, lymphatic and combined.
Each vascular defect was further classified into truncal
(T) and extratruncal (ET) forms, based on the
embryonic stage of developmental arrest.7–9,16
ET forms, develop from the earlier stages of
embryonic life at the reticular stage. They possess
embryonic characteristics of developmental potential
originating frommesenchymal cells (angioblasts). This
feature allows them to grow whenever stimulation
(e.g. trauma, surgery, hormonal therapy, pregnancy,
and menarche) is given. The ET form is furtherclassified by its clinical presentation as diffuse and
infiltrating or as limited and localised. T forms
develop from a later stage of embryonic life along
axial vessels and lack embryonic characteristics. The
haemodynamic impact of the T forms is more severe in
general than that of the ET form. A lesion is further
classified by its clinically presentation as either an
aplasia or as an obstruction type (e.g. hypoplasia,
aplasia, hyperplasia, stenosis, membrane, and con-
genital spur), or as a dilatation type (e.g. localised-
aneurysm and diffuse-ectasia).4,6 This concept fulfils
most of the requirements to provide aetiological,
anatomical and pathophysiological information
required for clinical management of CVMs. The
Hamburg classification further elucidated the unique
relationship between vascular malformations and
vascular tumours (infantile/neonatal haemangiomas)
to remove confusion concerning these two different
entitieswhichproduce similar vascular anomalies.2,17–19
We adopted this modified Hamburg classification4,6 as
the basis of a new structure of contemporary CVM
management at our clinic.CVMs and haemangiomas
CVMs and haemangioma are both categorised as
‘vascular anomalies’, but the conditions are entirely
different, so a precise understanding of their differ-
ences is essential for the proper diagnosis and
management of these conditions.
Haemangioma (infantile/neonatal) is the most
common tumour of infancy. It is a rapidly growing,
but self-limiting vascular tumour that usually appears
during the first 4 weeks of life. Explosive growth is
common, and is generally triggered postnatally, but
almost invariably undergoes spontaneous regression
before the age 5–7 years. The rapid growth of
haemangiomas is the result of endothelial prolifera-
tion with increased mitotic activity. In contrast CVMs
are not hypercellular and have a ‘mature’ endothelium
with normal endothelial mitotic activity, and grow pari
passu with the child.2,17–19 The differentiation of
haemangioma and CVM is generally possible given
the clinical history and the physical examination
alone. However, a deeply seated haemangioma in
subcutaneous tissue or muscle without involvement of
the papillary dermis can be confusing, and occasion-
ally needs histological confirmation. In addition to
their differentiation from haemangiomas, CVMs2,17–19
need to be differentiated from other vascular/non-
vascular conditions involving soft tissue (e.g. hae-
matoma, neurofibroma, and sarcoma). The proper
differentiation of CVMs from various malignantEur J Vasc Endovasc Surg Vol 30, August 2005
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consequences when overlooked.20-22 If any doubt
exists, a tissue biopsy should be obtained.Modalities of investigation (invasive and non-invasive)
A careful physical examination and detailed history
taking are most important for clinical diagnosis. The
clinical impression should be further confirmed by
laboratory evaluation to identify the characteristics of
the CVM, and its extent and degree of involvement.
This initial evaluation is based on minimally invasive
tests.1,3,10,11 Duplex ultrasonography (colour Doppler
imaging and spectral waveform analysis)23–25 is
excellent for haemodynamic assessment. It provides
information about blood flow, velocity, and volume
along the lesion as well as demonstrating its feeding
artery and draining vein. Airplethysmography (APG)
or venous photoplethysmography (PPG) is also
essential to determine the functional status of the
venous system. Infrared limb volumetry is indispen-
sable for general investigation of swellings of extre-
mities with CVM involvement. Transarterial lung
perfusion scintigraphy (TLPS),10,26 utilising Tc-99m
macroaggregated albumin, can provide essential
information on the arteriovenous (AV) shunting status
through an AV malformation (AVM), when it is
located in an extremity. This technique is extremely
informative not only for the initial evaluation, but also
for assessing result of treatment. Tc-99m RBC whole
body blood pool scintigraphy (WBBPS),1,10,11,13,27
known as ‘transvenous angioscan’, is able to detect
abnormal blood pooling throughout the body, and is
excellent at detecting VM, and AVM, and also for
ruling out lymphatic malformation (LM), though it
cannot differentiate CVMs from haemangiomas. TLPS
is excellent for the initial work-up of all CVMs and for
follow-up. Standard T1 and T2 weighted magnetic
resonance imaging (MRI) studies of CVMs22,28,29 are
essential to differentiate high flow from low flow
status. This technique has excellent ability to identify
VM, although some difficulty is experienced differen-
tiating haemangioma and LM. MR arteriography
(MRA) and MR venography (MRV) can be used as
options when standard MRI is insufficient (e.g. CVM
in the trunk). Computerised tomographic (CT) con-
trast studies including three-dimensional reconstruc-
tion are excellent at delineating AVM lesions. Tc-99m
antimony sulphide colloid lymphoscintigraphy30,31 is
also essential for the assessment of lymphatic function,
mostly for LMs and haemo-lymphatic malformation
(HLMs). Ultrasonographic lymphangiography and
MR lymphangiography can be used,10,30 mostly toEur J Vasc Endovasc Surg Vol 30, August 2005evaluate candidates for venolymphatic reconstructive
surgery with the T form of LM, although this is still in
the investigational stage. A comparative venous
oxygen saturation study of the affected extremity is
occasionally added given a differential diagnosis of
AVM.
Bone X-ray studies to assess long bone growth
discrepancies secondary to an intra- or extra-osseous
CVM are included to rule out vascular-bone syndrome
by any CVM involving the lower extremity. Such
studies are often combined with an assessment of the
spine and pelvic tilt.10,11
Invasive studies remain the reference standard for
the management of all CVMs. However, they are
generally used to decide upon the treatment plan, as
‘road maps’, though they may be used for the
differential diagnosis of a complex form of CVM.10,14
Ascending, descending, and multilevel regional veno-
graphy, and percutaneous direct puncture phlebogra-
phy are usedmainly to assess VM lesions and the deep
vein system. Standard selective and super-selective
arteriography are used for arterial malformations
(AMs) or AVMs; and direct puncture lymphangiogra-
phy for LMs. Detailed information from each test,
related to the investigation of various CVMs, has been
thoroughly assessed for findings, role, indication,
morbidity, and for technical information for to each
CVM type.1,10,13,26,27,30,31 Every test mentioned above
has a special role (e.g. WBBPS, TLPS) for the diagnosis
and for the management of the various CVMs, as
reviewed previously.10,22–30 Therefore, the precise
understanding of each test, is mandatory to ensure
that a proper combination of tests is used to achieve
synergism effect and a precise assessment.
The initial diagnostic (laboratory) procedure for a
CVM, following proper history taking and physical
examination should include a duplex scan, MRI, and
WBBPS as a basic test set. TLPS, lymphoscintigraphy,
CT contrast study and/or airplethysmography can be
added depending upon the kind of CVM (e.g. VM,
AVM, LM or HLM) and/or its type (e.g. T form or ET
form).
The risk and morbidity involved for the various
tests, should also be evaluated especially for paediatric
patients of less than 2 years old. Unless an accurate
diagnosis is immediately needed to allow urgent
treatment (e.g. a life or limb-threatening lesion, or a
lesion hampering vital functions), morbidity associ-
ated with diagnostic procedures may be deferred until
the child is old enough to tolerate them. Various
minimally invasive studies (e.g. MRI, duplex scan,
TLPS, and WBBPS) were sufficient to diagnose the
majority of CVMs at our clinic, and selective
invasive study (e.g. super-selective arteriography,
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was generally deferred until needed for treatment
purposes. The less invasive investigations are the
mainstay of our diagnostic strategy. Selective invasive
studies are reserved for treatment planning purposes.
Our multidisciplinary approach allowed the inte-
gration of diagnostic specialties and the sharing of
critical information obtained using the advanced
diagnostic techniques.1,32,33ManagementCare system
Our multidisciplinary approach promotes the role of
embolo-sclerotherapy as an independent as well as an
adjunctive therapy to surgery. The clinic has become
efficient by acting as a ‘referral centre’ facilitating the
efficient management of CVM problems by coordi-
nating the work of 15 clinical specialists, including; 11
Departments of Vascular Surgery, Paediatric Surgery,
Interventional, and Diagnostic Radiology, Plastic and
Reconstructive Surgery, Nuclear Medicine, Ortho-
paedic Surgery, Head andNeck Surgery, Oral-maxillary
Surgery, Anaesthesiology, Vascular Medicine, Pathol-
ogy, Physical Medicine and Rehabilitation, Psychiatry
and Dermatology.
The majority of the CVMs treated require the
involvement of most of the 15 specialists. This team
is led by vascular surgery and interventional radiology
specialists. Social service staff have played a crucial
role to solicit active involvement by patients and their
families through a self-help club.
The clinical management of the T form of lymphatic
malformation (LM) is performed through the Lym-
phoedema Clinic, along with primary and secondary
lymphoedemas of various aetiologies. The ET form of
LM, often called cystic or cavernous lymphangioma, is
treated at our CVM Clinic, as are other ETand T forms
of vascular malformation.Multidisciplinary approach
Each CVM patient needs to be thoroughly evaluated
by each clinic team member individually.1 The
summed results of the individual assessments are
fully discussed by the clinical board and the final
decision on management strategy arrived at by
consensus.9–12 The treatment plan may be adjusted
whenever a treatment strategy can be improved to
deal with morbidity or recurrence.1,10,11 The clinic
limits the treatment of a small number of conditions toan ‘absolute’ indication for treatment, but a ‘relative’
indication is more liberal and includes various
conditions which can be managed without significant
risk of morbidity (Table 1). Therefore, not all CVMs
warrant treatment nor is treatment feasible in some
cases within the resources of our clinic. Treatment is
commenced only when the benefit of treatment
exceeds the risks involved.1,11,13
The first decision made by the clinic team following
the confirmation of a diagnosis of CVM is whether the
patient needs treatment. Treatment decisions are made
when the patient has one absolute indication or two
relative indications (Table 1). Once the decision to treat
is made a treatment plan is devised. The best option
for management is selected from the available treat-
ment modalities.31 Multi-session embolo-sclero-
therapy is in general conducted with intervals of 1
month between sessions, with assessment following
each treatment. The treatment plan is reviewed
regularly to assess efficacy and complications. The
clinic teamwill modify the plan is necessary. A regular
review of the course of treated and untreated lesions
is also made periodically in addition, to provide
further optimum control and reinforce a life-time
commitment.10,34Outcome assessment
Clinical assessments are based on the subjective
improvement of clinical symptoms on a scale of 0–10
after the completion of multisession therapy. Each
symptom and sign, (e.g. pain, discomfort, ache,
stiffness, or limited joint motion or gait) the patient
has before starting the treatment is documented based
on descriptions by the patient, or by the patient’s
family members, and include medical photographs.
Objective evidence of improved clinical signs, e.g.
reduction in the size of a lesion or swelling, or an
improved range of motion of the joint on a scale 0–5,
or the classification of response as ‘excellent’, ‘good,’
or ‘fair.’.1,13
Laboratory assessments are based on combinations
of minimally invasive tests, such as duplex scanning,
WBBPS, TLPS, and MRI, especially for interim assess-
ment during multisession therapy. Angiographic
findings remain the reference standard for the assess-
ment of the treatment response, especially of an AVM.
At the conclusion of each treatment, and at the
completion of multisession therapy, ‘excellent’
describes complete control (disappearance), ‘good’
for near complete control with negligible evidence of
residual lesion, and ‘fair’ for substantial control with
significant residual lesion. Similar criteria are appliedEur J Vasc Endovasc Surg Vol 30, August 2005
Table 1. Treatment indication for congenital vascular malformations
Absolute* indication
Haemorrhage—mostly from the VM or AVM
Increasing or progressing risk of high-output heart failure—AVM
Secondary complication of chronic venous hypertension—AVM or VM
Lesions located at a life and/or limb threatening region (e.g. proximity to the airway)—VM or AVM
Lesions threatening vital functions (e.g. seeing, hearing, eating or breathing)—various CVMs
Relative* indications
Disabling pain and/or discomfort of a progressive nature
Functional disability or impairment affecting daily activity and the quality of life
Cosmetically severe deformity accompanying physical and/or psychological disability and severe negative impact on the quality of life
Vascular-bone syndrome with rapid progress of long bone growth discrepancy accompanied by significant pelvic tilt and/or compensatory
scoliosis
Lesions located at a region with a high risk of complication (e.g. haemarthrosis; deep vein thrombosis)
Lesions with recurrent infection and sepsis
* The consensus among multidisciplinary team of the CVM Clinic, Samsung Medical Center, Seoul, Korea.
B. B. Lee188to the results of tests used for treatment assessment.
For example, duplex ultrasonography assesses the
blood flow in a lesion. Complete cessation of flow at
the treated nidus is ‘excellent’. Near complete cessa-
tion, but with some suspicion along the feeding artery
and draining veins is ‘good’. Drastic reduction, but
with substantial evidence of residual activity of the
treated nidus is ‘fair’. Similar criteria are applied for
WBBPS, TLPS, and MRI. WBBPS provides more
quantitative measurement of outcome. On serial
tests, a reduction of 50% or more in the isotope label
is interpreted as ‘good’, and a reduction of 30–50% as
‘fair’. Periodical follow-up evaluations of treatment
results are made every 6 months by the multidisci-
plinary team. A proper combination of these tests
replaces classical angiography in monitoring progress
of treatment. Arteriography must be included in the
final confirmation of treatment results, and during
subsequent biannual follow-up as a routine protocol
for AVMs.TreatmentIndications
Treatment in principle is aimed at correction of
haemodynamic disturbances caused by CVM lesions.
Treatment strategies for the ‘primary malformation’
and for ‘secondary disorders’, especially of musculo-
skeletal and soft tissue systems are quite different.
Individual tailoring of the treatment strategy should
be made to meet the patient’s functional needs and
those of the specific underlying pathology.10,11
Absolute indications for treatment include: haem-
orrhage; lymphatic leakage with recurrent local or
systemic sepsis by LM or HLM; high output heart
failure or a secondary ischemic complications of an
AVM and chronic venous insufficiency secondary toEur J Vasc Endovasc Surg Vol 30, August 2005VM or HLM. CVM lesions located in a potentially life-
threatening region (e.g. adjacent to an airway), lesions
located in a limb threatening region and lesions
jeopardizing vital functions (e.g. seeing, hearing,
eating and breathing) are also considered to be
absolute indications for treatment (Table 1).
Relative indication for treatment include disabling
pain, usually attributable to non-healing ulcers,
lesions accompanied by functional impairment,
lesions located at regions with a high-risk of compli-
cation (e.g. haemarthrosis, deep vein thrombosis
and/or pulmonary embolism) and lesions causing a
cosmetically severe deformity reducing the quality of
life (Table 1).11Surgical therapy
We now use surgery in combination with embolo-
sclerotherapy rather than as an independent treatment
in the management of the ET form of various CVMs,13
reducing surgical morbidity. Pre- and post-operative
embolo-sclerotherapy can increase scope of surgical
therapy to various other ET forms. This strategy
allows treatment of complex forms of CVM which
was beyond the conventional approach.35,36
Surgical treatment alone or in conjunction with pre-
operative embolo-sclerotherapy, is still the best
method for the T form of various CVMs, especially
of VM (e.g. venous aneurysm and marginal vein)
where there is no risk of recurrence.37,38 Surgery is
more practical for the localised type of infiltrating Et
although there is a risk of recurrence. Surgical
procedures aimed at reducing the haemodynamic
impact of vascular defects must be given priority in
the management of CVMs.11 Reconstructive surgery
such as venous bypass to restore normal haemo-
dynamics, and ablative (excisional) surgery to remove
the vascular defect itself may be combined. These
haemodynamic operations are performed before
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secondary affects of primary CVM lesions.10 Most
reconstructive surgery is required to restore arterial
supply and venous outflow and is usually required to
manage the T form of VM (e.g. femoro-popliteal
venous bypass or the repair of femoral or popliteal
vein ectasia or aneurysm). Ablative surgery includes
excision of vascular defects either of the ET or T forms
(e.g. the removal of the marginal-lateral embryonic-
vein for the HLM) to eradicate the primary lesion and
does not need additional reconstructive surgery.10,11
Once haemodynamic surgery has been completed,
non-haemodynamic operations can be commenced.10,11
These aim at correcting the consequence of a CVM,
either caused by CVM treatment (e.g. Achilles tendon
contraction) or as a consequence of progression of
CVM lesions. These operations include orthopaedic
surgery to improve the function (e.g. Achilles tendon
lengthening) or plastic surgery to improve a cosmetic
deformity.
Complete resection of CVMs should be limited to
the isolated superficial lesion without extension into
the contiguous structure in order to minimise surgical
morbidity. An extensive lesion beyond the deep fascia
with the involvement of muscle, tendon or bone or
extending into the pelvis or gluteal region from the
extremity is not ideal for excisional surgery. Embolo-
sclerotherapy is used as the first line of treatment in
these cases and may be followed by surgery. Extreme
lesions with gross deformity and poor functional
status, especially of a lower limb, are considered for
early amputation and followed by fitting with a proper
prosthesis. This allows more rapid rehabilitation
rather than persisting with futile treatment.
The excisional surgery occasionally requires prepa-
ration for large blood loss, although pre-operative
embolo-sclerotherapy has substantially reduced this
requirement. We use several techniques for minimis-
ing blood loss including intraoperative hypotensive
anaesthesia, autotransfusion, rapid infusion, the use
of a proximal tourniquet, intraoperative embolo-
sclerotherapy, and even complete circulatory arrest
under deep hypothermia and an extra-corporeal
bypass procedure.Embolo-sclerotherapy
We use absolute ethanol, N-butyl cyanoacrylate
(NBCA), contour particles and coils for the embolo-
sclerotherapy of CVMs at our clinic.1,39–43 These
materials are safe, effective and reduce morbidity
and recurrence, particular in the diffuse infiltrating
extratruncal (ET) forms of VMs. This treatment isuseful where surgery would be difficult due to
extensive involvement beyond the deep fascia to
muscle, tendon, bone and joints. The diffuse infiltrat-
ing type of the extratruncal form of CVM is therefore
appropriately managed by this treatment. Pre-opera-
tive embolo-sclerotherapy improves the overall safety
and efficacy of surgery, reducing morbidity and
complications.26,27,31
Combinations of sclerosant drugs and embolisation
materials can be used to improve efficacy. Absolute
ethanol sclerotherapy is the preferred method of
treatment at our clinic for the infiltrating type of the
ET form, though this is accompanied by significant
morbidity.1,13 Absolute ethanol has given excellent
interim results with no evidence of recurrence during
the limited follow-up after more than 400 sessions of
treatment.1,13 Ethanol can be delivered percutaneously
directly into the nidus of the VM lesion by using the
direct puncture technique. N-butyl cyanoacrylate
(NBCA) embolotherapy also has been incorporated
into the management of extensive VM lesions prior to
surgery in order to minimise bleeding.
It is important to treat the nidus of an AVM lesion in
any type of AVM. The nidus should be reached via a
transarterial, transvenous, or direct puncture route
independently or simultaneously for precise control.
The old concept of ligating or blocking feeding vessels
must be condemned since, it may result in a rebound
phenomenon and unintentionally stimulate the nidus
into rapid growth with further deterioration.
Pre-operative NBCA embolisation has key role in
the management of AVMs. This treatment enhances
complete removal of the lesion and minimises bleed-
ing complications. However, NBCA is not an ideal
agent for the control of surgically-inaccessible diffuse
infiltrating ET forms of AVM as an independent
therapy. When a glue-filled lesion cannot be excised
the long-term effect on the endothelium of the AVM
nidus is uncertain as permanent means of preventing
recurrence. Absolute ethanol is better for non-resect-
able AVMs than glue, though the short-term risk of
morbidity and complications are increased. Ethanol
can be used alone using a multisession approach, or in
conjunction with any other modalities.1,13,44–47 We
have recently used NBCA in combination with ethanol
and coils, especially for the fistulous type of AVM.
In the case of LMs the indications for ethanol sclero-
therapy at our clinic are limited to the ET form, which
fail to respond to or is unsuitable for OK-432
sclerotherapy. OK-432 is recommended as a substitute
for absolute ethanol in the primary therapy of LMs,
especially for the cystic ET form, since, most LMs are
not life or limb-threatening, and therefore less power-
ful, safer drugs may be tried first.30,48,49 However,Eur J Vasc Endovasc Surg Vol 30, August 2005
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therapy for LMs has shown limited success at
reducing the surgical morbidity of the cavernous ET
form.30 Interstitial laser therapy of the cavernous ET
form of LM is under clinical trial for surgically
unresectable lesions, with mixed results.
For the HLM(s) representing the combined form of
CVM, which include VM, LM, CM (capillary malfor-
mation), and micro-AVM, each component has to be
managed separately as indicated for each CVM type
and form (T form or ET form).Drugs used for embolo-sclerotherapy
Numerous attempts have been made to develop
reliable, less dangerous drugs to fulfil the requirement
that they permanently destroy endothelial cells of
CVM ET forms and prevent recurrence. ET forms of
CVMs retain developmental potential from mesench-
ymal cells and can grow when stimulated by incom-
plete destruction.
Drugs using successfully for the management of
varicose veins, such as polidocanol, tetradecyl sul-
phate, sodium morrhuate, and ethanolamine, have
been investigated for efficacy in CVM sclero-
therapy.39–43,45–47 Absolute ethanol remains the most
reliable substance for permanently occluding periph-
eral arteries and veins although the risk of major
adverse effects (e.g. skin and soft tissue necrosis,
nerve damage, deep vein thrombosis) is signifi-
cant.1,13,41,42,45,46 Absolute ethanol permanently oblit-
erations the vessel lumen and provides the least
chance of recanalisation because it denatures blood
protein, dehydrates vascular endothelia cells, and
precipitates protoplasm.41,42,50,51 The majority of its
complications are minor and include skin erythema or
bullae.1,13 The severity of local complications is related
to the location of a lesion, i.e. close enough to the skin
dermis to allow the ethanol to influence the skin
resulting in vesicles, bullae, necrosis and ulceration.
Major complications include deep venous thrombosis,
pulmonary embolisation, peripheral nerve palsy, and
cartilage necrosis.1,13 Precautions should be taken to
avoid these whenever possible.10,31 Complications are
generally accepted by patients and physicians as
justifiable morbidities to obtain minimum recurrence.
However, the balance of benefit over anticipated
complications should be properly weighed. Transient
elevation of pulmonary arterial pressure is the most
common acute morbidity associated with ethanol
sclerotherapy, especially for high-flow lesions, due to
the reaction between the applied ethanol and the
pulmonary circulation. This is easily detected andEur J Vasc Endovasc Surg Vol 30, August 2005controlled with proper medication under close cardio-
pulmonary monitoring during general anaesthesia.
The successful control of the extensive infiltrating
types of VM within calf muscles by ethanol sclero-
therapy is often accompanied by calf muscle contrac-
ture. This can be successfully managed with vigorous
physical therapy sometimes necessitating surgical
Achilles tendon lengthening.
Absolute ethanol should only be used by experi-
enced personnel. The smallest dose possible should be
administered, based on the dose calculated for the
individual’s body weight. The total used in a session
should not exceed 1.0 ml of absolute ethanol per kg of
body weight. Increased risk of pulmonary hyperten-
sion is associated with repeated treatment sessions.
This should must be managed by nitro-glycerine
administration rather than calcium channel blockers,
because of its selective action on the venous system,
including the pulmonary artery, and its reduced
systemic effect.52–54ResultsCVMs in general: demographic data
Seven hundred and ninety seven patients (females:
446, males: 351, mean age of 22.1 years: range 14 days–
81 years) with various CVMs were registered at the
CVM clinic during the period January 1995–December
2001. Three hundred and fifteen patients were con-
firmed as LM (T form: 226 and ET form: 89); 294
patients as VM; 76 as AVM; and 66 as having the
combined form as HLM. The site of predilection of
CVMs was along the extremity (404/797: 324 lower
limbs and 80 upper limbs) followed by the head and
neck (179/797), though multiple locations was also
prevalent (163/797). Of these 797 patients, 327 (124
VM, 48 AVM, 127 LM and 28 HLM) were considered
appropriate for interventional treatment. The lesions
treated were located mostly in the head and neck
region (117/329), followed by the extremities (88/329)
and multiple (63/329) lesions.Venous malformation (VM)
A total of 294 patients (males: 138, females: 156, mean
age 18.6 years: range 3 months–59 years) were
confirmed as having VM mostly located in the
extremities (128/294: upper limbs: 30 and lower
limbs: 98), and often as a multiple lesions (73/294).
One hundred and twenty four of the 294, were selected
for treatment. Ninety-nine infiltrating ET forms,
Fig. 1. Management of venous malformation (VM) with absolute ethanol as an independent sclerotherapy. (A) and (B):
Clinical appearance of VM-affected right cheek, pre-operative (A) and post-operative (B). (C) and (D):Whole body blood pool
scan finding of a VM lesion over the right cheek lesion, pre-operative (C) and post-operative (D). (E): Phlebographic finding
of VM lesion in the cheek region via direct puncture. (F): Phlebographic finding of immediate sclerotherapy success via an
absolute ethanol injection into the nidus of the lesion. (G): Duplex scan finding of the haemodynamic condition at the internal
jugular vein draining the VM lesion-increased blood volume and vein diameter of IJV before the treatment (top two photos),
and decreased blood volume and vein diameter following treatment (bottom two photos). (H) and (I): MRI findings of a VM
lesion in the cheek and in the sublingual region, before treatment (H) and after treatment (I).
New Approach to Congenital Vascular Malformations 191unsuitable for surgical therapy, received a total of 419
sessions of ethanol sclerotherapy. Twenty-five limited
ET forms were excised surgically, though most under-
went pre-operative embolo-sclerotherapy (16/25) with
N-butyl cyanoacrylate (NBCA). Thirty-six sessions of
NBCA embolotherapy were given independently or in
conjunction with ethanol sclerotherapy as pre-opera-
tive adjunct therapy for the subsequent surgical
excision of 16 ET forms. Nine T forms (e.g. venectasia,
or venous aneurysm) underwent haemodynamic
operations to ligate and remove large vessels.
The 99 ET forms treated with ethanol sclerotherapy
showed an immediate success rate of 98.8% (414
sessions among 419 sessions). Failures were due to
direct connection between the lesion and the main
venous outflow, the close proximity of the lesion to the
skin and the consequent risk of skin necrosis (e.g.eyelid, face), technical difficulty in reaching the
residual nidus of the lesion, and the proximity of a
nerve. The interim results of ethanol sclerotherapy
were also excellent in the majority (89/99) with a fair
to good response and no evidence of recurrence of the
treated lesions during the limited average follow-up
period of 18.2 months. On average 3.2 sessions per
patient were required. (Fig. 1).
Sixteen ET forms, which underwent pre-operative
embolo-sclerotherapy and subsequent surgical exci-
sion showed excellent results in all with minimum
morbidity and no recurrence during the follow-up
period (average 21.2 months) (Fig. 2). Nine T
forms, underwent surgery with excellent results in
all. There were no chronic sequelae due to the
toxic effect of absolute ethanol on the pulmonary
vasculature.Eur J Vasc Endovasc Surg Vol 30, August 2005
Fig. 2. Management of a venous malformation (VM) by pre-operative embolisation and subsequent surgical excision. (A):
Clinical appearance of the VM lesion along the left buttock in a massively swollen condition. (B): WBBPS* finding of the
lesion involving the entire buttock. (C): TLPS* finding of the lesion without evidence of hidden AV-shunting condition. (D)
and (E): MRI finding of diffuse infiltrating extratruncal form of the VM lesion throughout the soft tissues and gluteal muscles.
(F): Angiographic finding of the pure venous nature of the lesion (AV shunting condition was ruled out). (G): Angiographic
finding of the pre-operative embolisation with N-butyl cyanoacrylate (NBCA) glue. (H): Pre-operative CTscan finding of the
glue-filled lesion as a road-map for subsequent surgical excision. (I): Pre-operative preparation status with volume expanders
along the massive lesion to achieve wound expansion. (J): Operative finding of the glue-filled lesion to reduce bleeding-
related morbidity. (K): Surgical specimen of the lesion safely resected with minimummorbidity. (L): Surgical wound, feasible
for primary closure without additional skin graft and/or flap rotation. *WBBPS, whole body blood pool scan; TLPS,
transarterial lung perfusion scan.
B. B. Lee192VM complications and morbidity
The 99 VM patients developed 101 ‘acute’ compli-
cations during 98 of 419 sessions (23.4% of sessions
and 50.5% of patients). Most were minor, and were
confined to skin and subcutaneous tissue injury, due to
the proximity of lesions to the skin (87/101). These
healed with standard wound care. Since, they were
mainly predictable (68/87) patients were forewarned,
and they were accepted in most cases as unavoidable
minor morbidities of the treatment. However, 9 with
skin complications involved deeper tissue injury
(e.g. muscle and/or tendon injury), which required
subsequent plastic reconstructive work (e.g. split-
thickness skin graft, etc.) to obtain healing.Eur J Vasc Endovasc Surg Vol 30, August 2005Deep vein thrombosis (DVT) developed in 8
sessions; one was complicated by an acute pulmonary
embolism (PE), and another by superficial throm-
bophlebitis. All lesions were located near the normal
deep vein system of the lower extremity, with direct
drainage of the VM lesion by connecting vessels into
the deep system. The transient elevation of pulmonary
artery pressure (PAP) as a signal of spilled ethanol
entering the systemic circulation did not occur in all 8
of these cases. Two DVTs complicated by PE devel-
oped more than 24 h after the third sessions had been
completed, but were accompanied by abnormal
coagulation profiles including protein C and protein
S deficiency. The DVTs were treated with low
molecular weight heparin and oral anticoagulation
Fig. 3.Management of the AVM by combination embolo-sclerotherapy using coils and ethanol simultaneously. (A): Clinical
appearance of a rapidly expanding AVM lesion with a painful swelling at the right forearm. (B): WBBPS* finding of a
haemodynamically active AVM lesion with a large abnormal blood pool at the right forearm. (C): TLPS* finding of AV
shunting status through the lesion nidus—25.43%. (D): Angiographic finding of the AVM lesion with rapid flow-
accompanying nidus. (E): Angiographic finding of the preliminary coil embolization (transarterial) to reduce the blood flow
through a nidus planned for subsequent ethanol treatment. (F): Angiographic finding of the lesion following the priming of
the nidus by coil embolisation for subsequent ethanol sclerotherapy. (G): Angiographic finding of the satisfactory result
following the completion of simultaneous embolo-sclerotherapywith coil and ethanol. *WBBPS, whole body blood pool scan;
TLPS, transarterial lung perfusion scan.
New Approach to Congenital Vascular Malformations 193with coumadin. No further complication or sequelae
occurred, and anticoagulation treatment was main-
tained for an average of 6 months.
Peripheral nerve damage, mostly peroneal, ulnar,
median or facial nerves, either as transient or
permanent damage, developed following 9 sessions
of treatment. Two were permanent, but the other 6
were transient and recovered within 2 weeks–2
months.
Chronic complications and morbidities developed
in 11 of 99 VM patients, 3–12 months after successful
sclerotherapy. Seven of these 11 patients had fibrosis of
the calf muscles and subsequently developed contrac-
ture of the ankle, requiring aggressive physicaltherapy to improve an abnormal gait. Five of these 7
achieved satisfactory compensation with physical
therapy and two patients required an early Achilles
tendon lengthening procedure to increase the efficacy
of physical therapy.
Transient pulmonary hypertension and transient
haematuria are reported as acute complications of
ethanol sclerotherapy.1,13 These developed in more
than two-thirds of the 419 sessions, but were all
managed safely using vasodilators. Nitroglycerine
given through the intravenous port of a Swan-Ganz
catheter (0.3–1.5 mg/kg of body weight/min) was
considered to be superior to calcium channel blockers
as it has less effect on the systemic circulation.31,52–54Eur J Vasc Endovasc Surg Vol 30, August 2005
B. B. Lee194Arteriovenous malformation (AVM)
Sixteen patients (extratruncal: 14; truncal: 2) of 48
patients with localised AVMs were selected for pre-
operative embolo-sclerotherapy. Twenty-four sessions
of embolo-sclerotherapy facilitated subsequent surgi-
cal excision. NBCA glue and additional ethanol were
used (NBCA glue only-9; NBCA glue and ethanol: 4;
ethanol only: 2; and ethanol and ivalon: 1). All patients
underwent surgical excision 2–4 weeks of the embolo-
sclerotherapy. This reduced morbidity by allowing
selective excision of the lesion. Minimal blood loss
occurred, averaging 200 ml, in contrast to the massive
blood loss of conventional surgical therapy. One
patient had a pulmonary embolism following the use
of NBCA glue. All 16 patients had excellent interim
results with no evidence of recurrence, during a
follow-up averaging 24.3 months.
Thirty-two patients (extratruncal: 28; truncal: 4)
with surgically inaccessible lesions, mostly diffuse
infiltrating AVMs (buttock; thigh, and calf muscles)
were managed by embolo-sclerotherapy alone. There
were 171 sessions with nine failures. Ethanol was
combined with coils, glues and/or contour particles
(in 158/162 of the successful sessions) mainly for high
flow fistulous lesions (Fig. 3). Ethanol was utilised
alone in 132 sessions. The majority (25/32 patients)
were considered to have an excellent result at an
average follow-up of 19.2 months. Good to fair control
of the activity of the nidus was observed among the
remaining seven. All had angiographic follow-up.
No evidence of recurrence was found during the
follow-up period of 19.2 months.AVM complications and morbidity
There were 31 complications, the majority (27/31) of
which were minor and involved the skin. This usually
followed ethanol treatment. Three of four major
complications developed after ethanol therapy: 1
transient facial nerve palsy, 1 deep vein thrombosis
and 1 massive ear cartilage necrosis. One pulmonary
embolism followed NBCA glue embolisation of an
AVM of the fistulous type. These major complications
developed in high-flow conditions, while the majority
of minor complications developed among extratruncal
AVMs. Treatment was stopped for one patient with a
high-flow AVM fistula involving bone, despite what
was considered good progress. Subsequently, the
patient required a forearm amputation to arrest
recurrent massive bleeding and high-output cardiac
failure as life-saving procedure. Unfortunately, the
patient eventually committed suicide.Eur J Vasc Endovasc Surg Vol 30, August 2005Lymphatic malformation (LM) (the T and ET forms)
Two hundred and twenty six cases of the T form of LM
clinically presented as chronic lymphoedema of the
congenital type (40/226), precox type (138/226), or
tarda type (48/226). They were affected by chronic
lymphoedema: 32 at stage I; 104 at stage II; 48 at stage
III; 18 at stage IV; and 24 at an undetermined stage.
The clinical response of the T form in clinical stages
I and II to manual lymphatic drainage (MLD)-based
complex decongestive physiotherapy (CDP) was
excellent to good, following initial in-hospital care in
the majority of cases (121/136). Some improvement
also occurred in stages III and IV (31/66), with a good
to fair response, despite additional SIPC-based com-
pressotherapy (38/66). The long-term maintenance of
the initial treatment results with excellent to good to
fair responses in a total of 152 cases (stages I through
IV), was found to be totally dependent on patient
compliance. In most cases (102/152), good compliance
with home-maintenance care was achieved for up to
48 months, the end-point of the follow-up assessment.
In addition to this, CDP-based conservative therapy as
a basic therapy for all 315 T forms, 15 patients with 19
T form limbs received further surgical therapy, either
reconstructive (10/19) or ablative (9/19).
Of a total of 32 cases who underwent reconstructive
surgery 10 patients (limbs) with primary lympho-
edema due to the T form of LM were treated by a
venolymphatic anastomosis (4/10) or a free lymph
node transplant (6/10), as a supplementary surgical
therapy when the clinical stage of the lymphoedema
progressed. Of 4 veno-lymphatic anastomotic recon-
structions performed for primary lymphoedema, only
2 showed good to fair maintenance of the initially
good results (6–12 months) at the end-point of the
follow-up (48 months). There was an accompanying
compatible improvement of lymphatic function by
lymphoscintigraphic evaluation, with reduced dermal
backflow and higher tracer clearance.
Four of 6 patients who underwent free lymph node
transplant surgery showed a good to fair response on
the initial evaluation (12 months), together with viable
lymph nodes (3/4) by ultrasound evaluation, and
functioning lymph nodes by lymphoscintigraphy
(2/4). Subsequently, 3 patients maintained a good to
excellent clinical response at the 24 month follow-up
assessment.
Of 22 patients at the end stage of chronic lympho-
edema who received ablative (excisional) surgery on
33 limbs, 9 limbs of 5 patients with primary lympho-
edema as a result of the T form of LM were included,
together with 24 limbs of secondary lymphoedema,
where the disease had progressed from stage III to IV
Fig. 4. Management of a lymphatic malformation (LM) with OK-432 and/or ethanol as an independent sclerotherapy. (A):
Clinical appearance of an LM-affected upper anterior-lateral-chest wall with recurrent local cellulitis, following an ill-
managed lesion surgically. (B): MRI finding of a primarily cystic type of an extratruncal form of an LM lesion. (C):
Angiographic findings of the superficial and/or de-novo lesion (neck) lesion treated with OK-432 and of the recurrent
and/or deep-seated lesion (chest wall) treated with ethanol.
New Approach to Congenital Vascular Malformations 195with an increased incidence of local and/or systemic
sepsis. This causes a rapid deterioration in the quality
of life, and/or an inability to apply CDP due to
massive swelling of the limb.
In 9 limbs, where excisional surgery for primary
lymphoedema was undertaken, only 6 were able to
maintain a good result for 48 months. However, all 6
cases that complied well with post-operative CDP
and/or compressotherapy maintained an acceptable
outcome. None showed improved lymphatic function
by follow-up lymphoscintigraphic evaluation.
Of 89 patients with the ET form of LM, 73 patients
were treated by sclerotherapy (62/73) or surgically
(11/73). Sixty-two patients, including most with the
cystic type, were treated by 120 sessions of sclero-
therapy with OK-432 (108/120) and absolute ethanol
(12/120) (Fig. 4). Eleven patients, includingmost of the
cavernous type, were treated by surgical excision; 7patients were treated using combined pre-operative
OK-432 sclerotherapy prior to the surgical excision,
and 4 patients were treated independently.
Of 62 patients, 51 patients selected from the
paediatric age group were treated only by OK-432
sclerotherapy over 108 sessions. Complete to marked
shrinkage was obtained in 88.9% of the limited cystic
type (40/45) and of 50% (3/6) of the diffuse infiltrating
cavernous type. There was only one recurrence during
the minimum follow-up period of 24 months.
Seventeen lesions (9-diffuse; 8-limited) of 7
patients underwent pre-operative OK-432 scler-
otherapy to reduce the magnitude of the sub-
sequent surgical excision. Fourteen of 17 lesions
showed good to excellent results with much
reduced morbidity and complications. There was
no evidence of recurrence during the minimum
follow-up period of 24 months.Eur J Vasc Endovasc Surg Vol 30, August 2005
B. B. Lee196DiscussionRecommendations
A new strategy based on the multi-disciplinary concept
has achieved significant improvements in the manage-
ment of CVMs, although this success has created new
problems of acute and chronic morbidity following
treatment. All presently available treatment modalities
have been carefully integrated to reduce the risk of
complications. No single treatment modality presently
available fulfils all treatment and cost requirements.
We adopted absolute ethanol as the main drug for
sclerotherapy despite the risk, because it can destroy
endothelial cells permanently minimising recurrence.
The use of absolute ethanol for the management of
CVM is acceptable if complications of treatment are
managed properly. We encountered a previously
unknown risk of ethanol sclerotherapy, when treating
the infiltrating type of VM lesion within the calf
muscle.1 The treatment was effective but progressive
muscle fibrosis with a subsequent contracture of the
calf muscles was more serious than expected. We
cannot over emphasise the need for continuous
attention and maximum effort to reduce both the
acute and chronic complications of absolute ethanol.
We do not recommend absolute ethanol for ‘routine’
use unless a specialised team approach is taken,
especially in the case of high flow AVM lesions.
The new strategy of combining embolisation
materials (e.g. coils, contour particles, N-butyl cyano-
acrylate) with absolute ethanol was introduced
recently to achieve synergistic effects and to reduce
the morbidity associated with absolute ethanol. This
new strategy seems to work well with the extensive
forms of VM and AVM, especially of the fistulous type
with high flow, which lacks an adequate nidus to
attack with ethanol alone. The strategy of converting a
fistulous lesion to a non-fistulous lesion by prelimi-
nary embolisation can substantially reduce the risks of
ethanol sclerotherapy.
In an attempt to replace ethanol, a trial with
polidocanol and tetradecyl sulphate foam has been
started for VM. This is delivered under duplex
ultrasound control. VMs involving the dermis or
critical areas (e.g. the face) were selected for this trial
since, ethanol would carry a considerable risk of
complications. Similar efforts have been made to treat
the less dangerous LM, or HLM with OK-432, also
known as picibanil, which is a streptococcal exotoxin
with LM specificity. This sclerosant seems to have a
reasonable future for LM as it provides the same
success rate as ethanol for the limited (cystic) type ofEur J Vasc Endovasc Surg Vol 30, August 2005the LM ET form, though its results are mixed for in
recurrent and diffuse (cavernous) types.Conclusion
A multidisciplinary team approach to CVMs has been
developed improving results of treatment, with
reduced morbidity and recurrence compared to
conventional approaches. New strategies that fully
integrate traditional surgical therapies with combi-
nations of embolisation and sclerotherapy are effective
in lesions, which once would have been impossible to
treat. This system of treatment aims to improve the
quality of life from this ever-miserable disease.Acknowledgements
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